{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:16:13Z","timestamp":1791260173896,"version":"4.1.0"},"reference-count":17,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T00:00:00Z","timestamp":1707868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Voriconazole is a broad-spectrum triazole antifungal agent recommended for invasive fungal diseases, including invasive aspergillosis. Therapeutic drug monitoring via voriconazole target trough concentration is important to ensure efficacy while preventing toxicity. Our aim was to determine the stability of voriconazole as adapted and measured by an immunoassay.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Plasma from patient samples (n = 45) evaluated by a liquid chromatography with tandem mass spectrometry (LC-MS\/MS) method was compared against an ARK immunoassay method, adapted and optimized on the Abbott Alinity c analyzer. Stability of voriconazole and analytical performance of ARK immunoassay was assessed, including functional sensitivity, limit of blank (LoB), limit of detection (LoD), and limit of quantification (LoQ), linearity, and precision.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>ARK voriconazole immunoassay was highly correlated (Pearson R = 0.988) to the LC-MS\/MS method, with an average bias of 0.09\u2005mg\/L (2%). CV at LoQ of 0.5\u2005mg\/L was 3.7% while the functional sensitivity was established at 0.05\u2005mg\/L. Overall imprecision with liquid quality control material obtained from ARK was 5.0%, 6.3%, and 5.9% at 1\u2005mg\/L, 5\u2005mg\/L, and 10\u2005mg\/L, respectively. Limit of blank and LoD were 0.02\u2005mg\/L and 0.05\u2005mg\/L, respectively. Voriconazole in lithium heparin plasma separator tube declines over time, with a decrease that is more evident near or above toxic concentrations.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Voriconazole collected in gel separation tubes declines over time, possibly due to absorptive properties. Voriconazole measurements by immunoassay and LC-MS\/MS demonstrated acceptable comparability with sufficient level of sensitivity and precision.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jalm\/jfad139","type":"journal-article","created":{"date-parts":[[2024,2,17]],"date-time":"2024-02-17T02:45:12Z","timestamp":1708137912000},"page":"565-572","source":"Crossref","is-referenced-by-count":3,"title":["Stability and Analytical Characterization of Voriconazole as Measured by Immunoassay"],"prefix":"10.1093","volume":"9","author":[{"given":"Veni","family":"Bharti","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine and Pathobiology, University of Toronto , Toronto, ON , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Jung","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathobiology, University of Toronto , Toronto, ON , Canada"},{"name":"Division of Clinical Biochemistry, Department of Paediatric Laboratory Medicine, The Hospital for Sick Children , Toronto, ON , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Lam","sequence":"additional","affiliation":[{"name":"Division of Clinical Biochemistry, Laboratory Medicine Program, University Health Network , Toronto, ON , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ansel","family":"Fabros","sequence":"additional","affiliation":[{"name":"Division of Clinical Biochemistry, Laboratory Medicine Program, University Health Network , Toronto, ON , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4457-616X","authenticated-orcid":false,"given":"Rajeevan","family":"Selvaratnam","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathobiology, University of Toronto , Toronto, ON , Canada"},{"name":"Division of Clinical Biochemistry, Laboratory Medicine Program, University Health Network , Toronto, ON , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,2,14]]},"reference":[{"key":"2024050218422659400_jfad139-B1","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis","volume":"347","author":"Herbrecht","year":"2002","journal-title":"N Engl J Med"},{"key":"2024050218422659400_jfad139-B2","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2024050218422659400_jfad139-B3","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","article-title":"Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper","volume":"46","author":"Abdul-Aziz","year":"2020","journal-title":"Intensive Care Med"},{"key":"2024050218422659400_jfad139-B4","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1086\/524669","article-title":"Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes","volume":"46","author":"Pascual","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2024050218422659400_jfad139-B5","doi-asserted-by":"crossref","first-page":"647","DOI":"10.2217\/pgs-2020-0029","article-title":"Strategy to effectively and efficiently implement voriconazole pharmacogenetics in clinical practice","volume":"21","author":"Garc\u00eda","year":"2020","journal-title":"Pharmacogenomics"},{"key":"2024050218422659400_jfad139-B6","doi-asserted-by":"crossref","first-page":"5497427","DOI":"10.1155\/2021\/5497427","article-title":"Determination of voriconazole plasma concentration by HPLC technique and evaluating its association with clinical outcome and adverse effects in patients with invasive aspergillosis","volume":"2021","author":"Yousefian","year":"2021","journal-title":"Can J Infect Dis Med Microbiol"},{"key":"2024050218422659400_jfad139-B7","doi-asserted-by":"crossref","DOI":"10.1177\/20420986221127503","article-title":"Therapeutic drug monitoring and safety evaluation of voriconazole in the treatment of pulmonary fungal diseases","volume":"13","author":"Shen","year":"2022","journal-title":"Ther Adv Drug Saf"},{"key":"2024050218422659400_jfad139-B8","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ijantimicag.2014.07.013","article-title":"Efficacy and safety of voriconazole and CYP2C19 polymorphism for optimised dosage regimens in patients with invasive fungal infections","volume":"44","author":"Wang","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"2024050218422659400_jfad139-B9","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ijantimicag.2015.12.003","article-title":"Impact of CYP2C19 genetic polymorphisms on voriconazole dosing and exposure in adult patients with invasive fungal infections","volume":"47","author":"Lamoureux","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"2024050218422659400_jfad139-B10","first-page":"19","article-title":"Principles and applications of liquid chromatography-mass spectrometry in clinical biochemistry","volume":"30","author":"Pitt","year":"2009","journal-title":"Clin Biochem Rev"},{"key":"2024050218422659400_jfad139-B11","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1258\/0004563011900641","article-title":"Automated immunoassay analysers","volume":"38","author":"Wheeler","year":"2001","journal-title":"Ann Clin Biochem"},{"key":"2024050218422659400_jfad139-B12","doi-asserted-by":"crossref","first-page":"5303","DOI":"10.1128\/AAC.00404-10","article-title":"Multiplex ultra-performance liquid chromatography-tandem mass spectrometry method for simultaneous quantification in human plasma of fluconazole, itraconazole, hydroxyitraconazole, posaconazole, voriconazole, voriconazole-N-oxide, anidulafungin, and caspofungin","volume":"54","author":"Decosterd","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2024050218422659400_jfad139-B13","article-title":"The forgotten mountain plot\u2014an illustration of bias across lipase methods","volume":"2","author":"Leung","year":"2024","journal-title":"J Appl Lab Med"},{"key":"2024050218422659400_jfad139-B14","author":"Potapov"},{"issue":"Suppl 1","key":"2024050218422659400_jfad139-B15","first-page":"S49","article-title":"Limit of blank, limit of detection and limit of quantitation","volume":"29","author":"Armbruster","year":"2008","journal-title":"Clin Biochem Rev"},{"key":"2024050218422659400_jfad139-B16","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.cca.2016.08.014","article-title":"Where clinical chemistry meets medicinal chemistry. Systematic analysis of physico-chemical properties predicts stability of common used drugs in gel separator serum tubes","volume":"462","author":"Steuer","year":"2016","journal-title":"Clin Chim Acta"},{"key":"2024050218422659400_jfad139-B17","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.clinbiochem.2022.08.009","article-title":"Evaluation of serum and rapid serum separator collection tubes for therapeutic drug assays","volume":"115","author":"Garza","year":"2023","journal-title":"Clin Biochem"}],"container-title":["The Journal of Applied Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jalm\/article-pdf\/9\/3\/565\/57388981\/jfad139.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jalm\/article-pdf\/9\/3\/565\/57388981\/jfad139.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T18:44:29Z","timestamp":1714675469000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jalm\/article\/9\/3\/565\/7608191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,14]]},"references-count":17,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,2,14]]},"published-print":{"date-parts":[[2024,5,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jalm\/jfad139","relation":{},"ISSN":["2475-7241"],"issn-type":[{"value":"2475-7241","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,5]]},"published":{"date-parts":[[2024,2,14]]}}}